Fingerprint
Dive into the research topics of 'Switching from originator to biosimilar infliximab in paediatric inflammatory bowel disease is feasible and uneventful'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Switching from originator to biosimilar infliximab in paediatric inflammatory bowel disease is feasible and uneventful
Lisa Gervais (Lead / Corresponding author), Luke L. McLean, Michelle L. Wilson, Carol Cameron, Lee Curtis, Vikki Garrick, Kat Armstrong, Rachel Tayler, Paul Henderson, Richard Hansen, Iain Chalmers, David C. Wilson, Richard K. Russell
Research output: Contribution to journal › Article › peer-review
26
Citations
(Scopus)